
Citation: Manishtha Rao, Madhvi Awasthi. A review on interventions to prevent osteoporosis and improve fracture healing in osteoporotic patients[J]. AIMS Medical Science, 2020, 7(4): 243-268. doi: 10.3934/medsci.2020015
[1] | Jing Huang, Qian Wang, Rui Zhang . On a binary Diophantine inequality involving prime numbers. AIMS Mathematics, 2024, 9(4): 8371-8385. doi: 10.3934/math.2024407 |
[2] | Jing Huang, Ao Han, Huafeng Liu . On a Diophantine equation with prime variables. AIMS Mathematics, 2021, 6(9): 9602-9618. doi: 10.3934/math.2021559 |
[3] | Bingzhou Chen, Jiagui Luo . On the Diophantine equations $x^2-Dy^2=-1$ and $x^2-Dy^2=4$. AIMS Mathematics, 2019, 4(4): 1170-1180. doi: 10.3934/math.2019.4.1170 |
[4] | Jing Huang, Wenguang Zhai, Deyu Zhang . On a Diophantine equation with four prime variables. AIMS Mathematics, 2025, 10(6): 14488-14501. doi: 10.3934/math.2025652 |
[5] | Hunar Sherzad Taher, Saroj Kumar Dash . Repdigits base $ \eta $ as sum or product of Perrin and Padovan numbers. AIMS Mathematics, 2024, 9(8): 20173-20192. doi: 10.3934/math.2024983 |
[6] | Liuying Wu . On a Diophantine equation involving fractional powers with primes of special types. AIMS Mathematics, 2024, 9(6): 16486-16505. doi: 10.3934/math.2024799 |
[7] | Ashraf Al-Quran . T-spherical linear Diophantine fuzzy aggregation operators for multiple attribute decision-making. AIMS Mathematics, 2023, 8(5): 12257-12286. doi: 10.3934/math.2023618 |
[8] | Cheng Feng, Jiagui Luo . On the exponential Diophantine equation $ \left(\frac{q^{2l}-p^{2k}}{2}n\right)^x+(p^kq^ln)^y = \left(\frac{q^{2l}+p^{2k}}{2}n\right)^z $. AIMS Mathematics, 2022, 7(5): 8609-8621. doi: 10.3934/math.2022481 |
[9] | Jinyan He, Jiagui Luo, Shuanglin Fei . On the exponential Diophantine equation $ (a(a-l)m^{2}+1)^{x}+(alm^{2}-1)^{y} = (am)^{z} $. AIMS Mathematics, 2022, 7(4): 7187-7198. doi: 10.3934/math.2022401 |
[10] | Sohail Ahmad, Ponam Basharat, Saleem Abdullah, Thongchai Botmart, Anuwat Jirawattanapanit . MABAC under non-linear diophantine fuzzy numbers: A new approach for emergency decision support systems. AIMS Mathematics, 2022, 7(10): 17699-17736. doi: 10.3934/math.2022975 |
In many areas of the objective world, such as target tracking, machine learning system identification, associative memories, pattern recognition, solving optimization problems, image processing, signal processing, and so on [1,2,3,4,5], a lot of practical problems can be described by delay differential equations (DDEs). Therefore, the research of delay differential equations has been the subject of significant attention [6,7]. As we all know, time delays are inevitable in population dynamics models. For example, the maturation period should be considered in the study of simulated biological species [8,9], incubation periods should be considered in epidemiology area [7], and the synaptic transmission time among neurons should be considered in neuroscience field [10]. In particular, the dynamic behavior of most cellular neural network models is significantly affected by time delay, so the investigation on delayed cellular neural networks has been the world-wide focus.
It should be mentioned that proportional delay is one of important time-varying delays, which is unbounded and monotonically increasing, and is more predictable and controllable than constant delay and bounded time-varying delay. Over past decade, by introducing proportional time delay, investigations of the following neutral type proportional delayed cellular neural networks (CNNs) with D operators:
[xi(t)−pi(t)xi(rit)]′=−ai(t)xi(t)+n∑j=1eij(t)fj(xj(t))+n∑j=1bij(t)gj(xj(qijt))+Ii(t),t≥t0>0, i∈N={1,2,⋯,n}, | (1.1) |
with initial value conditions:
xi(s)=φi(s), s∈[ρit0, t0], φi∈C([ρit0, t0],R), ρi=min{ri,min1≤j≤n{qij}}, i∈N, | (1.2) |
have attracted great attention of some researchers. The main reason is that its successful applications in variety of areas such as optimization, associative memories, signal processing, automatic control engineering and so on (see [11,12,13,14,15] and the references therein). Here n is the number of units in a neural network, (x1(t),x2(t),⋯,xn(t))T corresponds to the state vector, the decay rate at time t is designated by ai(t), coefficients pi(t), eij(t) and bij(t) are the connection weights at the time t, fj and gj are the activation functions of signal transmission, ri(t)≥0 denotes the transmission delay, ri and qij are proportional delay factors and satisfy 0<ri, qij<1, Ii(t) is outside input.
As pointed out by the authors of reference [16], the weighted pseudo almost periodic function consists of an almost periodic process plus a weighted ergodic component. It is well known that the weighted pseudo-almost periodic phenomenon is more common in the environment than the periodic, almost periodic and pseudo-almost periodic phenomenon, so the dynamic analysis of the weighted pseudo-almost periodic is more realistic [17,18,19,20]. Furthermore, when pi(t)≡0, the existence and exponential stability of weighted pseudo almost periodic solutions (WPAPS) of proportional delayed cellular neural networks (CNNs)
x′i(t)=−ai(t)xi(t)+n∑j=1eij(t)fj(xj(t))+n∑j=1bij(t)gj(xj(qijt))+Ii(t), t≥t0>0, i∈N, | (1.3) |
have been established in [22] under the following conditions
supt∈R{−˜ai(t)+Ki[ξ−1in∑j=1(|eij(t)|Lfj+|bij(t)|Lgj)ξj]}<−γi. | (1.4) |
{Here, for i∈N, ˜ai∈C(R, (0, +∞)) is a bounded function, and Ki>0 is a constant with
e−∫tsai(u)du≤Kie−∫ts˜ai(u)du for all t,s∈R and t−s≥0. |
In addition, fj and gj are the activation functions with Lipschitz constants Lfj and Lgj obeying
|fj(u)−fj(v)|≤Lfj|u−v|, |gj(u)−gj(v)|≤Lgj|u−v| for all u,v∈R, i∈N. |
} It should be mentioned that the authors in [22] use (1.4) to show that there exists a constant λ∈(0,mini∈N˜a−i) such that
Πi(λ)=supt∈R{λ−˜ai(t)+Ki[ξ−1in∑j=1(|eij(t)|Lfj+|bij(t)|Lgjeλ(1−qij)t)ξj]}<0, i∈N. | (1.5) |
With the aid of the fact that limt→+∞eλ(1−qij)t=+∞, it is easy to see that (1.4) can not lead to (1.5). Meanwhile, Examples 4.1 and 4.2 in [22] also have the same error, where
bij(t)=110(i+j)sin2t, i,j=1,2, |
and
b1j(t)=1100(cos(1+j)t),b2j(t)=1100(cos(1+j)t+cos√2t),b3j(t)=1100(cos(1+j)t+sin√2t),}j=1,2,3, |
can not also meet (1.5). For detail, the biological explanations on equations (1.4) and (1.5) can be found in [22]. Now, in order to improve [22], we will further study the existence and exponential stability of weighted pseudo almost periodic solutions for (1.1) which includes (1.3) as a special case. Moreover, this class of models has not been touched in the existing literature.
On account of the above considerations, in this article, we are to handle the existence and generalized exponential stability of weighted pseudo almost periodic solutions for system (1.1). Readers can find the following Remark 2.1 for extensive information. In a nutshell, the contributions of this paper can be summarized as follows. 1) A class of weighted pseudo almost periodic cellular neural network model with neutral proportional delay is proposed; 2) Our findings not only correct the errors in [22], but also improve and complement the existing conclusions in the recent publications [22,23]; 3) Numerical simulations including comparison analyses are presented to verify the obtained theoretical results.
The remainder of the paper is organized as follows. We present the basic notations and assumptions in Section 2. The existence and exponential stability of weighted pseudo almost periodic solutions for the addressed neural networks models are proposed in Section 3. The validity of the proposed method is demonstrated in Section 4, and conclusions are drawn in Section 5.
Notations. R and Rn denote the set of real numbers and the n-dimensional real spaces. For any x={xij}∈Rmn, let |x| denote the absolute value vector given by |x|={|xij|}, and define ‖x‖=maxij∈J|xij(t)|. Given a bounded continuous function h defined on R, let h+=supt∈R|h(t)|, h−=inft∈R|h(t)|. We define U be the collection of functions (weights) μ:R→(0,+∞) satisfying
U∞:={μ | μ∈U,infx∈Rμ(x)=μ0>0}, |
and
U+∞:={μ|μ∈U∞,lim sup|x|→+∞μ(αx)μ(x)<+∞,lim supr→+∞μ([−αr, αr])μ([−r, r])<+∞, ∀α∈(0,+∞)}. |
Let BC(R,Rn) denote the collection of bounded and continuous functions from R to Rn. Then (BC(R,Rn),‖⋅‖∞) is a Banach space, where ‖f‖∞:=supt∈R‖f(t)‖. Also, this set of the almost periodic functions from R to Rn will be designated by AP(R,Rn). Furthermore, the class of functions PAPμ0(R,Rn) be defined as
PAPμ0(R,Rn)={φ∈BC(R,Rn)|limr→+∞1μ([−r, r])∫r−rμ(t)|φ(t)|dt=0}. |
A function f∈BC(R,Rn) is said to be weighted pseudo almost periodic if there exist h∈AP(R,Rn) and φ∈PAPμ0(R,Rn) satisfying
f=h+φ, |
where h and φ are called the almost periodic component and the weighted ergodic perturbation of weighted pseudo almost periodic function f, respectively. We designate the collection of such functions by PAPμ(R,Rn). In addition, fixed μ∈U+∞, (PAPμ(R,Rn),‖.‖∞) is a Banach space and AP(R,Rn) is a proper subspace of PAPμ(R,Rn). For more details about the above definitions can be available from [17,18] and the references cited therein.
In what follows, for i,j∈N, we shall always assume that eij,bij,pi,Ii∈PAPμ(R,R), and
ai∈AP(R,R), M[ai]=limT→+∞1T∫t+Ttai(s)ds>0. | (2.1) |
For i,j∈N, we also make the following technical assumptions:
(H1) there are a positive function ˜ai∈BC(R,R) and a constant Ki>0 satisfying
e−∫tsai(u)du≤Kie−∫ts˜ai(u)du for all t,s∈R and t−s≥0. |
(H2) there exist nonnegative constants Lfj and Lgj such that
|fj(u)−fj(v)|≤Lfj|u−v|,|gj(u)−gj(v)|≤Lgj|u−v| for all u,v∈R. |
(H3) μ∈U+∞, we can find constants ξi>0 and Λi>0 such that
supt∈R1˜ai(t)Ki[|ai(t)pi(t)|+ξ−1in∑j=1(|eij(t)|Lfj+|bij(t)|Lgj)ξj]<Λi, |
supt≥t0{−˜ai(t)+Ki[|ai(t)pi(t)|11−p+i+ξ−1in∑j=1|eij(t)|Lfjξj11−p+j+ξ−1in∑j=1|bij(t)|Lgjξj11−p+j]}<0, |
and
p+i+Λi<1, i∈N. |
Remark 2.1. From (H1) and (H2), one can use an argument similar to that applied in Lemma 2.1 of [24] to demonstrate that every solution of initial value problem (1.1) and (1.2) is unique and exists on [t0, +∞).
In this section, we will establish some results about the global generalized exponential stability of the weighted pseudo almost periodic solutions of (1.1). To do this end, we first show the following Lemma.
Lemma 3.1. (see[[22], Lemma 2.1]). Assume that f∈PAPμ(R,R) and β∈R∖{0}. Then, f(βt)∈PAPμ(R,R).
Using a similar way to that in lemma 2.3 of [22], we can show the following lemma:
Lemma 3.2. Assume that (H1) and (H2) hold. Then, the nonlinear operator G:
(Gφ)i(t)=∫t−∞e−∫tsai(u)du[−ai(s)pi(s)φi(ris)+ξ−1in∑j=1eij(s)fj(ξjφj(s))+ξ−1in∑j=1bij(s)gj(ξjφj(qijs))+ξ−1iIi(s)]ds, i∈N, φ∈PAPμ(R,Rn), |
maps PAPμ(R,Rn) into itself.
Theorem 3.1. Suppose that (H1), (H2) and (H3) are satisfied. Then, system (1.1) has exactly one WPAPS x∗(t)∈PAPμ(R,Rn), which is globally generalized exponentially stable, that is, for every solution x(t) agreeing with (1.1)−(1.2), there exists a constant σ∈(0,mini∈N˜a−i) such that
xi(t)−x∗i(t)=O((11+t)σ) as t→+∞ for all i∈N. |
Proof. With the help of (H3), it is easy to see that there are constants σ,λ∈(0, mini∈N˜a−i) such that
p+ieσln1ri<1, supt∈Reλ˜ai(t)Ki[|ai(t)pi(t)|+ξ−1in∑j=1(|eij(t)|Lfj+|bij(t)|Lgj)ξj]<Λi, i∈N, | (3.1) |
and
supt≥t0{σ−˜ai(t)+Ki[|ai(t)pi(t)|11−p+ieσln1rieσln1ri+ξ−1in∑j=1|eij(t)|Lfjξj11−p+jeσln1rj+ξ−1in∑j=1|bij(t)|Lgjξj11−p+jeσln1rjeσln(1qij)]}<0, i∈N, | (3.2) |
which, along with the inequalities
σ1+t≤σ, ln(1+t1+rit)≤ln1ri, ln(1+t1+qijt)≤ln1qij for all t≥0, i,j∈N, |
yield
supt≥t0{σ1+t−˜ai(t)+Ki[|ai(t)pi(t)|11−p+ieσln1rieσln1+s1+rit+ξ−1in∑j=1|eij(t)|Lfjξj11−p+jeσln1rj+ξ−1in∑j=1|bij(t)|Lgjξj11−p+jeσln1rjeσln(1+t1+qijt)]}≤supt≥t0{σ−˜ai(t)+Ki[|ai(t)pi(t)|11−p+ieσln1rieσln1ri+ξ−1in∑j=1|eij(t)|Lfjξj11−p+jeσln1rj+ξ−1in∑j=1|bij(t)|Lgjξj11−p+jeσln1rjeσln(1qij)]}<0, i∈N. | (3.3) |
Consequently, applying a transformation:
yi(t)=ξ−1ixi(t), Yi(t)=yi(t)−pi(t)yi(rit), i∈N, |
leads to
Y′i(t)=−ai(t)Yi(t)−ai(t)pi(t)yi(rit)+ξ−1in∑j=1eij(t)fj(ξjyj(t))+ξ−1in∑j=1bij(t)gj(ξjyj(qijt))+ξ−1iIi(t), i∈N. | (3.4) |
Now, define a mapping P:PAPμ(R,Rn)→PAPμ(R,Rn) by setting
(Pφ)i(t)=pi(t)φi(rit)+(Gφ)i(t) for all i∈N, φ∈PAPμ(R,Rn), | (3.5) |
it follows from Lemma 3.1 and Lemma 3.2 that Pφ∈PAPμ(R,Rn).
Moreover, by means of (H1), (H2) and (H3), for φ,ψ∈PAPμ(R,Rn), we have
|(Pφ)i(t)−(Pψ)i(t)|=|pi(t)[φi(rit)−ψi(rit)]+∫t−∞e−∫tsai(u)du[ξ−1in∑j=1eij(s)(fj(ξjφj(s))−fj(ξjψj(s)))+ξ−1in∑j=1bij(s)(gj(ξjφj(qijs))−gj(ξjψj(qijs)))]ds|≤{p+i+∫t−∞e−∫ts˜ai(u)duKi[ξ−1in∑j=1(|eij(s)|Lfj+|bij(s)|Lgj)ξj]ds}‖φ(t)−ψ(t)‖∞≤{pi+Λi∫t−∞e−∫ts˜ai(u)du1eλ˜ai(s)ds}‖φ(t)−ψ(t)‖∞≤{pi+Λi1eλ}‖φ(t)−ψ(t)‖∞, |
which and the fact that 0<maxi∈N{p+i+Λi}<1 suggest that the contraction mapping P possesses a unique fixed point
y∗={y∗i(t)}∈PAPμ(R,Rn), Py∗=y∗. |
Thus, (1.5) and (3.5) entail that x∗={x∗i(t)}={ξiy∗i(t)}∈PAPμ(R,Rn) is a weighted pseudo almost periodic solution of (1.1).
Finally, we demonstrate that x∗ is exponentially stable.
Designate x(t)={xi(t)} be an arbitrary solution of (1.1) with initial value φ(t)={φi(t)} satisfying (1.2).
Label
xi(t)=φi(t)=φi(σit0), for all t∈[riσit0, σit0], | (3.6) |
yi(t)=ξ−1ixi(t), y∗i(t)=ξ−1ix∗i(t),zi(t)=yi(t)−y∗i(t)),Zi(t)=zi(t)−pi(t)zi(rit), i∈N. |
Then
Z′i(t)=−ai(t)Zi(t)−ai(t)pi(t)zi(rit)+ξ−1in∑j=1eij(t)(fj(ξjyj(t))−fj(ξjy∗j(t)))+ξ−1in∑j=1bij(t)(gj(ξjyj(qijt))−gj(ξjy∗j(qijt))), i∈N. | (3.7) |
Without loss of generality, let
‖φ−x∗‖ξ=maxi∈N{supt∈[ρit0,t0]ξ−1i|[φi(t)−pi(t)φi(rit)]−[x∗i(t)−pi(t)x∗i(rit)]|}>0, | (3.8) |
and M be a constant such that
M>N∑i=1Ki+1. | (3.9) |
Consequently, for any ε>0, it is obvious that
|Zi(t)|<M(‖φ−x∗‖ξ+ε)e−σln1+t1+t0 for all t∈(ρit0, t0], i∈N. | (3.10) |
Now, we validate that
‖Z(t)‖<M(‖φ−x∗‖ξ+ε)e−σln1+t1+t0 for all t>t0. | (3.11) |
Otherwise, there must exist i∈N and θ>t0 such that
{|Zi(θ)|=M(‖φ−x∗‖ξ+ε)e−σln1+θ1+t0, ‖Z(t)‖<M(‖φ−x∗‖ξ+ε)e−σln1+t1+t0 for all t∈(ρit0, θ). | (3.12) |
Furthermore, from (3.6), we obtain
eσln1+ν1+t0|zj(ν)|≤eσln1+ν1+t0|zj(ν)−pj(ν)zj(rjν)|+eσln1+ν1+t0|pj(ν)zj(rjν)|≤eσln1+ν1+t0|Zj(ν)|+p+jeσln1+ν1+rjνeσln1+rjν1+t0|zj(rjν)|≤M(‖φ−x∗‖ξ+ε)+p+jeσln1rjsups∈[rjρjt0, rjt]eσln1+s1+t0|zj(s)|≤M(‖φ−x∗‖ξ+ε)+p+jeσln1rjsups∈[ρit0, t]eσln1+s1+t0|zj(s)|, | (3.13) |
for all ν∈[ρjt0, t], t∈[t0, θ), j∈J, which entails that
eσln1+t1+t0|zj(t)|≤sups∈[ρjt0, t]eσln1+s1+t0|zj(s)|≤M(‖φ−x∗‖ξ+ε)1−p+jeσln1rj, | (3.14) |
for all t∈[ρit0, θ), j∈N.
Note that
Z′i(s)+ai(s)Zi(s)=−ai(s)pi(s)zi(ris)+ξ−1in∑j=1eij(s)(fj(ξjyj(s))−fj(ξjy∗j(s)))+ξ−1in∑j=1bij(s)(gj(ξjyj(qijs))−gj(ξjy∗j(qijs))), s∈[t0,t], t∈[t0,θ]. | (3.15) |
Multiplying both sides of (3.15) by e∫st0ai(u)du, and integrating it on [t0,t], we get
Zi(t)=Zi(t0)e−∫tt0ai(u)du+∫tt0e−∫tsai(u)du[−ai(s)pi(s)zi(ris)+ξ−1in∑j=1eij(s)(fj(ξjyj(s))−fj(ξjy∗j(s)))+ξ−1in∑j=1bij(s)(gj(ξjyj(qijs))−gj(ξjy∗j(qijs)))]ds, t∈[t0,θ]. |
Thus, with the help of (3.3), (3.9), (3.12) and (3.14), we have
|Zi(θ)|=|Zi(t0)e−∫θt0ai(u)du+∫θt0e−∫θsai(u)du[−ai(s)pi(s)zi(ris)+ξ−1in∑j=1eij(s)(fj(ξjyj(s))−fj(ξjy∗j(s)))+ξ−1in∑j=1bij(s)(gj(ξjyj(qijs))−gj(ξjy∗j(qijs)))]ds|≤(‖φ−x∗‖ξ+ε)Kie−∫θt0˜ai(u)du+∫θt0e−∫θs˜ai(u)duKi[|−ai(s)pi(s)zi(ris)|+ξ−1in∑j=1|eij(s)|Lfjξj|zj(s)|+ξ−1in∑j=1|bij(s)|Lgjξj|zj(qijs)|]ds≤(‖φ−x∗‖ξ+ε)Kie−∫θt0˜ai(u)du+∫θt0e−∫θs˜ai(u)duKi[|ai(s)pi(s)|M(‖φ−x∗‖ξ+ε)1−p+ieσln1rie−σln1+ris1+t0+ξ−1in∑j=1|eij(s)|LfjξjM(‖φ−x∗‖ξ+ε)1−p+jeσln1rje−σln1+s1+t0+ξ−1in∑j=1|bij(s)|LgjξjM(‖φ−x∗‖ξ+ε)1−p+jeσln1rje−σln1+qijs1+t0]ds=M(‖φ−x∗‖ξ+ε)e−σln1+θ1+t0{KiMe−∫θt0[˜ai(u)−σ1+u]du+∫θt0e−∫θs[˜ai(u)−σ1+u]duKi[|ai(s)pi(s)|11−p+ieσln1rieσln1+s1+ris+ξ−1in∑j=1|eij(s)|Lfjξj11−p+jeσln1rj+ξ−1in∑j=1|bij(s)|Lgjξj11−p+jeσln1rjeσln(1+s1+qijs)]ds}≤M(‖φ−x∗‖ξ+ε)e−σln1+θ1+t0{KiMe−∫θt0[˜ai(u)−σ1+u]du+∫θt0e−∫θs[˜ai(u)−σ1+u]duKi[|ai(s)pi(s)|11−p+ieσln1rieσln1ri+ξ−1in∑j=1|eij(s)|Lfjξj11−p+jeσln1rj+ξ−1in∑j=1|bij(s)|Lgjξj11−p+jeσln1rjeσln(1qij)]ds}≤M(‖φ−x∗‖ξ+ε)e−σln1+θ1+t0[1−(1−KiM)e−∫θt0(˜ai(u)−σ1+u)du]<M(‖φ−x∗‖ξ+ε)e−σln1+θ1+t0. |
This is a clear contradiction of (3.12). Hence, (3.11) holds. When ε⟶0+, we obtained
‖Z(t)‖≤M‖φ−x∗‖ξe−σln1+θ1+t0 for all t>t0. | (3.17) |
Then, using a similar derivation in the proof of (3.13) and (3.14), with the help of (3.17), we can know that
eσln1+t1+t0|zj(t)|≤sups∈[ρjt0, t]eσln1+s1+t0|zj(s)|≤M‖φ−x∗‖ξ1−p+jeσln1rj, |
and
|zj(t)|≤M‖φ−x∗‖ξ1−p+jeσln1rj(1+t01+t)σ for all t>t0, j∈N. |
The proof of the Theorem 3.1 is now finished.
Theorem 3.2. Let μ∈U+∞. Assume that (H1) and (H2) hold, and there exist constants γi,ξi>0 such that
supt∈R{−˜ai(t)+Ki[ξ−1in∑j=1(|eij(t)|Lfj+|bij(t)|Lgj)ξj]}<−γi for all i∈N, | (3.18) |
holds. Then, system (1.3) has a unique WPAPS x∗(t)∈PAPμ(R,Rn), and there is a constant σ∈(0,mini∈N˜a−i) such that
xi(t)−x∗i(t)=O((11+t)σ) as t→+∞, |
here i∈N, x(t) is an arbitrary solution of system (1.3) with initial conditions:
xi(s)=φi(s), s∈[ρ∗it0, t0], φi∈C([ρ∗it0, t0],R), ρ∗i=min1≤j≤n{qij}, i∈N. |
Proof. From (3.18) we can pick a positive constant Λ∗i such that
supt∈R1˜ai(t)Ki[ξ−1in∑j=1(|eij(t)|Lfj+|bij(t)|Lgj)ξj]<Λ∗i<1, i∈N. | (3.19) |
According to fact that (1.3) is a special case of (1.1) with p+i=0 (i∈N), the proof proceeds in the same way as in Theorem 3.1.
Remark 3.1. Obviously, it is easy to see that all results in [22] are the special case of Theorem 2.2 in this manuscript. In particular, the wrong in (1.5) has been successfully corrected. This indicates that our results supplement and improve the previous references [22,23]
In order to reveal the correctness and feasibility of the obtained results, an example with the simulation is introduced in this section.
Example 4.1. Consider the following CNNs with D operator and multi-proportional delays:
{[x1(t)−sint100x1(13t)]′=−(15+310sin20t)x1(t)+120(sin2t+e−t2(sint)2)120arctan(x1(t))+120(sin3t+e−t4(sint)4)120arctan(x2(t))+120(cos2t+e−t2(cost)2)120x1(12t)+120(cos3t+e−t4(cost)4)120x2(13t)+e−t2+sin(√3t),[x2(t)−cost100x2(13t)]′=−(15+310cos20t)x2(t)+120(cos2t+e−t2(cost)2)120arctan(x1(t))+120(cos3t+e−t4(cost)4)120arctan(x2(t))+120(cos3t+e−t6(cost)6)120x1(13t)+120(cos5t+e−t8(cost)8)120x2(14t)+e−t4+sin(√5t). | (4.1) |
Clearly,
n=2, qij=1i+j, t0=1, fi(x)=120arctanx, gi(x)=120x, i,j=1,2. |
Then, we can take
˜ai(t)=15, ξi=1, Lfi=Lgi=120, Ki=e310, μ(t)=t2+1, i,j=1,2, |
such that CNNs (1.1) with (4.1) satisfies all the conditions (H1)−(H3). By Theorem 2.1, we can conclude that CNNs (4.1) has a unique weighted pseudo almost periodic solution x∗(t)∈PAPμ(R,R2), and every solutions of (4.1) is exponentially convergent to x∗(t) as t→+∞. Here, the exponential convergence rate σ≈0.01. Simulations in Figure 1 reflect that the theoretical convergence is in sympathy with the numerically observed behaviors.
As far as we know, the weighted pseudo almost periodic dynamics of cellular neural networks with D operator and multi-proportional delays has never been studied in the previous literature [29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52]. It is easy to see that all results in [16,17,18,19,20,21,22,23,24,25,26,27,28] cannot be directly applied to show the case that all solutions of (4.1) converge globally to the weighted pseudo almost periodic solution. In particular, all parameters in system (4.1) are chosen by applying Matlab software. It should be mentioned that the nonlinear activation function fi(x)=120arctanx has been usually used as the sigmoid functions to agree with the experimental data of signal transmission in the real cellular networks networks.
In this paper, we investigate the global dynamic behaviors on a class of neutral type CNNs with D operator and multi-proportional delays. Some new criteria have been gained to guarantee that the existence and exponential stability of weighted pseudo almost periodic solutions for the addressed system by combining the fixed point theorem and some differential inequality techniques. The obtained results are new and complement some corresponding ones of the existing literature. It should be mentioned that the technical assumptions can be easily checked by simple algebra methods and convenient for application in practice. In addition, this method affords a possible approach to study the weighted pseudo dynamics of other cellular neural networks with D operator and delays. In the future, we will make this further research.
The author would like to express his sincere appreciation to the editor and reviewers for their helpful comments in improving the presentation and quality of the paper. This work was supported by the Postgraduate Scientific Research Innovation Project of Hunan Province (No. CX20200892) and "Double first class" construction project of CSUST in 2020 ESI construction discipline, Grant No. 23/03.
We confirm that we have no conflict of interest.
[1] |
Kilbanski A, Adams-Campbell L, Bassford T, et al. (2001) Osteoporosis prevention, diagnosis and therapy. JAMA 285: 785-795. doi: 10.1001/jama.285.6.785
![]() |
[2] | U.S. National Library of Medicine Medline Plus. Osteoporosis–overview. [Accessed September 22, 2017]. Updated September 2017. Available from: http://bit.ly/2sQEYYg. |
[3] |
Gomez-Cabello A, Ara I, Gonzalez-Agüero A, et al. (2012) Effects of training on bone mass in older adults: A systematic review. Sports Med 42: 301-325. doi: 10.2165/11597670-000000000-00000
![]() |
[4] |
Nguyen ND, Ahlborg HG, Center JR, et al. (2007) Residual lifetime risk of fracture in women and men. J Bone Miner Res 22: 781-788. doi: 10.1359/jbmr.070315
![]() |
[5] |
Melton LJ, Chrischilles EA, Cooper C, et al. (1992) Perspective. How many women have osteoporosis? J Bone Miner Res 7: 1005-1010. doi: 10.1002/jbmr.5650070902
![]() |
[6] |
Center JR, Bliuc D, Nguyen TV, et al. (2007) Risk of subsequent fracture after low trauma fracture in men and women. JAMA 297: 387-394. doi: 10.1001/jama.297.4.387
![]() |
[7] |
Bolander ME (1992) Regulation of fracture repair by growth factors. Proc Soc Exp Biol Med 200: 165-170. doi: 10.3181/00379727-200-43410A
![]() |
[8] |
Einhorn TA (1998) The cell and molecular biology of fracture healing. Clin Orthop Relat Res 355: S7-S21. doi: 10.1097/00003086-199810001-00003
![]() |
[9] |
Ferguson C, Alpern E, Miclau T, et al. (1999) Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 87: 57-66. doi: 10.1016/S0925-4773(99)00142-2
![]() |
[10] |
Gerstenfeld LC, Cullinane DM, Barnes GL, et al. (2003) Fracture healing as a post-natal developmental process: Molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88: 873-884. doi: 10.1002/jcb.10435
![]() |
[11] |
Vortkamp A, Pathi S, Peretti GM, et al. (1998) Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech Dev 71: 65-76. doi: 10.1016/S0925-4773(97)00203-7
![]() |
[12] |
Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367: 2010-2018. doi: 10.1016/S0140-6736(06)68891-0
![]() |
[13] |
Dennison E, Medley J, Cooper C (2006) Who is at risk of osteoporosis? Women's Health Med 3: 152-154. doi: 10.1383/wohm.2006.3.4.152
![]() |
[14] | Bonnick SL (1998) Bone Densitometry in Clinical Practice New Jersey: Humana Press Inc.. |
[15] |
Binkley N, Adler R, Bilezikian JP, et al. (2014) Osteoporosi diagnosis in men: The T-score controversy revisited. Curr Osteoporor Rep 12: 403-409. doi: 10.1007/s11914-014-0242-z
![]() |
[16] |
Kanis JA, Johansson H, Harvey NC, et al. (2018) A brief history of FRAX. Arch Osteoporos 13: 118. doi: 10.1007/s11657-018-0510-0
![]() |
[17] |
Kanis JA, Johnell O, Oden A, et al. (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385-397. doi: 10.1007/s00198-007-0543-5
![]() |
[18] |
Lorentzon M, Cummings SR (2015) Osteoporosis: The evolution of a diagnosis. J Intern Med 277: 650-661. doi: 10.1111/joim.12369
![]() |
[19] |
Deloumeau A, Molto A, Roux C, et al. (2017) Determinants of short-term fracture risk in patients with a recent history of low-trauma non-vertebral fracture. Bone 105: 287-291. doi: 10.1016/j.bone.2017.08.018
![]() |
[20] |
Ferrari SL, Abrahamsen B, Napoli N, et al. (2018) Diagnosis and management of bone fragility in diabetes: AN emerging challenge. Osteoporos Int 29: 2585-2596. doi: 10.1007/s00198-018-4650-2
![]() |
[21] |
Cummings SR, Black DM, Rubin SM (1989) Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149: 2445-2448. doi: 10.1001/archinte.1989.00390110045010
![]() |
[22] |
Butcher JL, MacKenzie EJ, Cushing B, et al. (1996) Long term outcomes after low extremity trauma. J Trauma 41: 4-9. doi: 10.1097/00005373-199607000-00002
![]() |
[23] | MacKenzie EJ, Bose MJ, Pollak AN, et al. (2005) Long term persistence of disability following severe lower limb trauma. Results of a seven year follow up. J Bone Joint Surg Am 87: 1801-1809. |
[24] |
Qaseem A, Snow V, Shekelle P, et al. (2008) Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians. Ann Intern Med 149: 404-415. doi: 10.7326/0003-4819-149-6-200809160-00007
![]() |
[25] |
Russell RG (2011) Bisphosphonates: The first 40 years. Bone 49: 2-19. doi: 10.1016/j.bone.2011.04.022
![]() |
[26] |
Odvina CV, Zerwekh JE, Rao DS, et al. (2005) Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294-1301. doi: 10.1210/jc.2004-0952
![]() |
[27] |
Yates J (2013) A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporos Int 24: 253-262. doi: 10.1007/s00198-012-2179-3
![]() |
[28] |
Zhang J, Wang R, Zhao YL, et al. (2012) Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis. Asian Pac J Trop Med 5: 743-748. doi: 10.1016/S1995-7645(12)60118-7
![]() |
[29] |
Crandall CJ, Newberry SJ, Diamant A, et al. (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: An updated systematic review. Ann Intern Med 161: 711-723. doi: 10.7326/M14-0317
![]() |
[30] |
Barrionuevo P, Kapoor E, Asi N, et al. (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis. J Clin Endocrinol Metab 104: 1623-1630. doi: 10.1210/jc.2019-00192
![]() |
[31] |
Freemantle N, Cooper C, Diez-Perez A, et al. (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: A meta-analysis. Osteoporos Int 24: 209-217. doi: 10.1007/s00198-012-2068-9
![]() |
[32] |
Hak DJ, Fitzpatrick D, Bishop JA, et al. (2014) Delayed union and nonunions: Epidemiology, clinical issues, and financial aspects. Injury 45: S3-S7. doi: 10.1016/j.injury.2014.04.002
![]() |
[33] |
Hegde V, Jo JE, Andreopoulou P, et al. (2016) Effect of osteoporosis medications on fracture healing. Osteoporos Int 27: 861-871. doi: 10.1007/s00198-015-3331-7
![]() |
[34] |
Saito T, Sterbenz JM, Malay S, et al. (2017) Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: Systematic review and meta-analysis. Osteoporos Int 28: 3289-3300. doi: 10.1007/s00198-017-4175-0
![]() |
[35] |
Duckworth AD, McQueen MM, Tuck CE, et al. (2019) Effect of alendronic acid on fracture healing: A multicenter randomized placebo-controlled trial. J Bone Miner Res 34: 1025-1032. doi: 10.1002/jbmr.3679
![]() |
[36] |
Lim EJ, Kim JT, Kim CH, et al. (2019) Effect of preoperative bisphosphonate treatment on fracture healing after internal fixation treatment of intertrochanteric femoral fractures. Hip Pelvis 31: 75-81. doi: 10.5371/hp.2019.31.2.75
![]() |
[37] |
Goodship AE, Walker PC, McNally D, et al. (1994) Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5: S53-S55. doi: 10.1093/annonc/5.suppl_2.S53
![]() |
[38] |
Peter CP, Cook WO, Nunamaker DM, et al. (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14: 74-79. doi: 10.1002/jor.1100140113
![]() |
[39] |
Miettinen SS, Jaatinen J, Pelttari A, et al. (2009) Effect of locally administered zoledronic acid on injury-induced intramembranous bone regeneration and osseointegration of a titanium implant in rats. J Orthop Sci 14: 431-436. doi: 10.1007/s00776-009-1352-9
![]() |
[40] |
Skripitz R, Johansson HR, Ulrich SD, et al. (2009) Effect of alendronate and intermittent parathyroid hormone on implant fixation in ovariectomized rats. J Orthop Sci 14: 138-143. doi: 10.1007/s00776-008-1311-x
![]() |
[41] |
Goldhahn J, Feron JM, Kanis J, et al. (2012) Implications for fracture healing of current and new osteoporosis treatments: An ESCEO consensus paper. Calcif Tissue Int 90: 343-353. doi: 10.1007/s00223-012-9587-4
![]() |
[42] |
Gerstenfeld LC, Sacks DJ, Pelis M, et al. (2009) Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 24: 196-208. doi: 10.1359/jbmr.081113
![]() |
[43] |
Adami S, Libanati C, Boonen S, et al. (2012) Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: Results from the freedom trial. J Bone Jt Surg Am 94: 2113-2119. doi: 10.2106/JBJS.K.00774
![]() |
[44] |
Hanley DA, Adachi JD, Bell A, et al. (2012) Denosumab: Mechanism of action and clinicaloutcomes. Int J Clin Pract 66: 1139-1146. doi: 10.1111/ijcp.12022
![]() |
[45] |
Bone HG, Bolognese MA, Yuen CK, et al. (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in post menopausal women with low bone mass. J Clin Endocrinol Metab 96: 972-980. doi: 10.1210/jc.2010-1502
![]() |
[46] |
Papaionnou A, Morin S, Cheung AM, et al. (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ 182: 1864-1873. doi: 10.1503/cmaj.100771
![]() |
[47] |
Russell RG, Rogers MJ (1999) Bisphophonates: From the laboratory to clinic and back again. Bone 25: 97-106. doi: 10.1016/S8756-3282(99)00116-7
![]() |
[48] |
Papapoulos S, Chapurlat R, Libanati C, et al. (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res 27: 694-701. doi: 10.1002/jbmr.1479
![]() |
[49] |
Seeman E, Delmas PD, Henley DA, et al. (2010) Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. J Bone Miner Res 25: 1886-1894. doi: 10.1002/jbmr.81
![]() |
[50] |
Lv F, Cai X, Yang W, et al. (2020) Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systemic review and meta-analysis. Bone 130: 115121. doi: 10.1016/j.bone.2019.115121
![]() |
[51] |
Riggs BL, Khosla S, Melton LJ (2002) Sex steroids and the construction and conservation of the adult skeleton. Endo Rev 23: 279-302. doi: 10.1210/edrv.23.3.0465
![]() |
[52] |
Sahiner T, Aktan E, Kaleli B, et al. (1998) The effects of postmenopausal hormone replacement therapy on sympathetic skin response. Maturitas 30: 85-88. doi: 10.1016/S0378-5122(98)00049-8
![]() |
[53] | Cho CH, Nuttall ME (2001) Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert Opin Emerg Drugs 6: 137-154. |
[54] |
Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators–mechanisms of action and application to clinical practice. N Engl J Med 348: 618-629. doi: 10.1056/NEJMra022219
![]() |
[55] |
Nilsson S, Koehler KF (2005) Oestrogen receptors and selective oestrogen receptor modulators: Molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 96: 15-25. doi: 10.1111/j.1742-7843.2005.pto960103.x
![]() |
[56] |
Gennari L, Merlotti D, Valleggi F, et al. (2007) Selective estrogen receptor modulators for postmenopausal osteoporosis: Current state of development. Drugs Aging 24: 361-379. doi: 10.2165/00002512-200724050-00002
![]() |
[57] |
Gennari L, Merlotti D, De Paola V, et al. (2008) Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag 4: 1229-1242. doi: 10.2147/TCRM.S3476
![]() |
[58] |
Delmas PD, Bjarnason NH, Mitlak BH, et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647. doi: 10.1056/NEJM199712043372301
![]() |
[59] |
Lufkin EG, Whitaker MD, Nickelsen T, et al. (1998) Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res 13: 1747-1754. doi: 10.1359/jbmr.1998.13.11.1747
![]() |
[60] |
Ettinger B, Black DM, Mitlak BH, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) Investigators. JAMA 282: 637-645. doi: 10.1001/jama.282.7.637
![]() |
[61] |
Maricic M, Adachi JD, Sarkar S, et al. (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162: 1140-1143. doi: 10.1001/archinte.162.10.1140
![]() |
[62] |
Langdahl BL, Silverman S, Fujiwara S, et al. (2018) Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone 116: 58-66. doi: 10.1016/j.bone.2018.07.013
![]() |
[63] | Lou S, Lv H, Wang G, et al. (2016) The effect of teriparatide on fracture healing of osteoporotic patients: A meta-analysis of randomized controlled trials. Biomed Res Int . |
[64] |
Kim SM, Kang KC, Kim JW, et al. (2017) Current role and application of teriparatide in fracture healing of osteoporotic patients: A systematic review. J Bone Metab 24: 65-73. doi: 10.11005/jbm.2017.24.1.65
![]() |
[65] |
Johansson T (2016) PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. A randomized, controlled study of 40 patients. Acta Orthop 87: 79-82. doi: 10.3109/17453674.2015.1073050
![]() |
[66] |
Huang TW, Chuang PY, Lin SJ, et al. (2016) Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures. Medicine (Baltimore) 95: e3626. doi: 10.1097/MD.0000000000003626
![]() |
[67] |
Kim SJ, Park HS, Lee DW, et al. (2019) Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures. Injury 50: 1364-1370. doi: 10.1016/j.injury.2019.06.002
![]() |
[68] |
Bernhardsson M, Aspenberg P (2018) Abaloparatide versus teriparatide: A head to head comparison of effects on fracture healing in mouse models. Acta Orthop 89: 674-677. doi: 10.1080/17453674.2018.1523771
![]() |
[69] |
Miller PD, Hattersley G, Riis BJ, et al. (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA 316: 722-733. doi: 10.1001/jama.2016.11136
![]() |
[70] |
Miller PD, Hattersley G, Lau E, et al. (2018) Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone 120: 137-140. doi: 10.1016/j.bone.2018.10.015
![]() |
[71] |
Langdahl BL, Silverman S, Fujiwara S, et al. (2018) Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone 116: 58-66. doi: 10.1016/j.bone.2018.07.013
![]() |
[72] |
Wojda SJ, Donahue SW (2018) Parathyroid hormone for bone regeneration. J Orthop Res 36: 2586-2594. doi: 10.1002/jor.24075
![]() |
[73] | Cheng ZY, Ye T, Ling QY, et al. (2018) Parathyroid hormone promotes osteoblastic differentiation of endothelial cells via the extracellular signal-regulated protein kinase 1/2 and nuclear factor-kappaB signaling pathways. Exp Ther Med 15: 1754-1760. |
[74] |
Swarthout JT, D'Alonzo RC, Selvamurugan N, et al. (2002) Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282: 1-17. doi: 10.1016/S0378-1119(01)00798-3
![]() |
[75] |
Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by wnt signaling. J Clin Investig 116: 1202-1209. doi: 10.1172/JCI28551
![]() |
[76] |
Sims NA, Ng KW (2014) Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Curr Osteoporos Rep 12: 98-106. doi: 10.1007/s11914-014-0196-1
![]() |
[77] |
Wan M, Yang C, Li J, et al. (2008) Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 22: 2968-2979. doi: 10.1101/gad.1702708
![]() |
[78] |
Li X, Zhang Y, Kang H, et al. (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280: 19883-19887. doi: 10.1074/jbc.M413274200
![]() |
[79] |
Koide M, Kobayashi Y (2018) Regulatory mechanisms of sclerostin expression during bone remodeling. J Bone Miner Metab 37: 9-17. doi: 10.1007/s00774-018-0971-7
![]() |
[80] |
Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37: 148-158. doi: 10.1016/j.bone.2005.03.018
![]() |
[81] |
Pazianas M (2015) Anabolic effects of PTH and the “anabolic window”. Trends Endocrinol Metab 26: 111-113. doi: 10.1016/j.tem.2015.01.004
![]() |
[82] |
Chandler H, Lanske B, Varela A, et al. (2018) Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone 120: 148-155. doi: 10.1016/j.bone.2018.10.012
![]() |
[83] |
Kakar S, Einhorn TA, Vora S, et al. (2007) Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 22: 1903-1912. doi: 10.1359/jbmr.070724
![]() |
[84] |
Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14: 960-968. doi: 10.1359/jbmr.1999.14.6.960
![]() |
[85] |
Yu M, D'Amelio P, Tyagi AM, et al. (2018) Regulatory T cells are expanded by teriparatide treatment in humans and mediate intermittent PTH-induced bone anabolism in mice. EMBO Rep 19: 156-171. doi: 10.15252/embr.201744421
![]() |
[86] |
Liu Y, Wang L, Kikuiri T, et al. (2011) Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 17: 1594-1601. doi: 10.1038/nm.2542
![]() |
[87] |
Subbiah V, Madsen VS, Raymond AK, et al. (2010) Of mice and men: Divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21: 1041-1045. doi: 10.1007/s00198-009-1004-0
![]() |
[88] |
Lou S, Lv H, Li Z, et al. (2018) Parathyroid hormone analogues for fracture healing: Protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open 8: e019291. doi: 10.1136/bmjopen-2017-019291
![]() |
[89] | Ozturan KE, Demir B, Yucel I, et al. (2011) Effect of strontium ranelate on fracture healing in the osteoporotic rats. J Orthop Res 24: 1651-1661. |
[90] |
Li YF, Luo E, Feng G, et al. (2011) Systemic treatment with strontium ralenate promotes tibial fracture healing in the osteoporotic rats. J Orthop Res 29: 138-142. doi: 10.1002/jor.21204
![]() |
[91] | Tarantino U, Celi M, Saturnino L, et al. (2010) Strontium ralenate and bone healing: Report of two cases. Clin Cases Miner Bone Metab 7: 65-68. |
[92] |
Alegre DN, Ribeiro C, Sousa C, et al. (2012) Possible benefits of strontium ralenate in complicated long bone fractures. Rheumatol Int 32: 439-443. doi: 10.1007/s00296-010-1687-8
![]() |
[93] |
Scaglione M, Fabbri L, Casella F, et al. (2016) Strontium ranelate as an adjuvant for fracture healing: Clinical, radiological, and ultrasound findings in a randomized controlled study on wrist fractures. Osteoporos Int 27: 211-218. doi: 10.1007/s00198-015-3266-z
![]() |
[94] | Murray SS, Murray BEJ, Wang JC, et al. (2016) The history and histology of bone morphogenetic protein. Histol Histopathol 31: 721-732. |
[95] |
Canalis E, Economides AN, Gazzerro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24: 218-235. doi: 10.1210/er.2002-0023
![]() |
[96] |
Onishi T, Ishidou Y, Nagamine T, et al. (1998) Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats. Bone 22: 605-612. doi: 10.1016/S8756-3282(98)00056-8
![]() |
[97] |
Pluhar GE, Turner AS, Pierce AR, et al. (2006) A comparison of two biomaterial carriers for osteogenic protein-1 (BMP-7) in an ovine critical defect model. J Bone Jt Surg Br 88: 960-966. doi: 10.1302/0301-620X.88B7.17056
![]() |
[98] |
Sawyer AA, Song SJ, Susanto E, et al. (2009) The stimulation of healing within a rat calvarial defect by mPCL-TCP/collagen scaffolds loaded with rhBMP-2. Biomaterials 30: 2479-2488. doi: 10.1016/j.biomaterials.2008.12.055
![]() |
[99] |
Cipitria A, Reichert JC, Epari DR, et al. (2013) Polycaprolactone scaffold and reduced rhBMP-7 dose for the regeneration of critical-sized defects in sheep tibiae. Biomaterials 34: 9960-9968. doi: 10.1016/j.biomaterials.2013.09.011
![]() |
[100] |
Guzman JZ, Merrill RK, Kim JS, et al. (2017) Bone morphogenetic protein use in spine surgery in the United States: How have we responded to the warnings? Spine J 17: 1247-1254. doi: 10.1016/j.spinee.2017.04.030
![]() |
[101] |
Carragee EJ, Hurwitz EL, Weiner BK (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J 11: 471-491. doi: 10.1016/j.spinee.2011.04.023
![]() |
[102] |
James AW, LaChaud G, Shen J, et al. (2016) A Review of the clinical side effects of bone morphogenetic protein 2. Tissue Eng Part B Rev 22: 284-297. doi: 10.1089/ten.teb.2015.0357
![]() |
[103] |
Glaeser JD, Salehi K, Kanim LEA, et al. (2018) Anti-inflammatory peptide attenuates edema and promotes bmp-2-induced bone formation in spine fusion. Tissue Eng Part A 24: 1641-1651. doi: 10.1089/ten.tea.2017.0512
![]() |
[104] |
Bara JJ, Dresing I, Zeiter S, et al. (2018) A doxycycline inducible, adenoviral bone morphogenetic protein-2 gene delivery system to bone. J Tissue Eng Regen Med 12: e106-e118. doi: 10.1002/term.2393
![]() |
[105] |
Kolk A, Tischer T, Koch C, et al. (2016) A novel nonviral gene delivery tool of BMP-2 for the reconstitution of critical-size bone defects in rats. J Biomed Mater Res A 104: 2441-2455. doi: 10.1002/jbm.a.35773
![]() |
[106] |
Wang M, Park S, Nam Y, et al. (2018) Bone-fracture-targeted dasatinib-oligoaspartic acid conjugate potently accelerates fracture repair. Bioconjug Chem 29: 3800-3809. doi: 10.1021/acs.bioconjchem.8b00660
![]() |
[107] |
Li X, Ominsky MS, Niu QT, et al. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 223: 860-869. doi: 10.1359/jbmr.080216
![]() |
[108] |
Van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE (2017) Sclerostin deficiency in humans. Bone 96: 51-62. doi: 10.1016/j.bone.2016.10.010
![]() |
[109] |
Koide M, Kobayashi Y (2019) Regulatory mechanisms of sclerostin expression during bone remodeling. J Bone Miner Metab 37: 9-17. doi: 10.1007/s00774-018-0971-7
![]() |
[110] |
Regard JB, Zhong Z, Williams BO, et al. (2012) Wnt signaling in bone development and disease: Making stronger bone with Wnts. Cold Spring Harb Perspect Biol 4: a007997. doi: 10.1101/cshperspect.a007997
![]() |
[111] |
Shi C, Li J, Wang W, et al. (2011) Antagonists of LRP6 regulate PTH-induced cAMP generation. Ann N Y Acad Sci 1237: 39-46. doi: 10.1111/j.1749-6632.2011.06226.x
![]() |
[112] |
Wijenayaka AR, Kogawa M, Lim HP, et al. (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6: e25900. doi: 10.1371/journal.pone.0025900
![]() |
[113] |
Alaee F, Virk MS, Tang H, et al. (2014) Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model. J Orthop Res 32: 197-203. doi: 10.1002/jor.22498
![]() |
[114] |
Ominsky MS, Brown DL, Van G, et al. (2015) Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone 81: 380-391. doi: 10.1016/j.bone.2015.08.007
![]() |
[115] |
Cosman F, Crittenden DB, Ferrari S, et al. (2018) Frame Study: The foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33: 1219-1226. doi: 10.1002/jbmr.3427
![]() |
[116] |
Graeff C, Campbell GM, Pena J, et al. (2015) Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone 81: 364-369. doi: 10.1016/j.bone.2015.07.036
![]() |
[117] |
Saag KG, Petersen J, Brandi ML, et al. (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377: 1417-1427. doi: 10.1056/NEJMoa1708322
![]() |
[118] |
Weske S, Vaidya M, Reese A, et al. (2018) Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat Med 24: 667-678. doi: 10.1038/s41591-018-0005-y
![]() |
[119] |
Xu R, Yallowitz A, Qin A, et al. (2018) Targeting skeletal endothelium to ameliorate bone loss. Nat Med 24: 823-833. doi: 10.1038/s41591-018-0020-z
![]() |
[120] |
Baltzer AWA, Whalen JD, Wooley P, et al. (2001) Gene therapy for osteoporosis: Evaluation in a murine ovariectomy model. Gene Ther 8: 1770-1776. doi: 10.1038/sj.gt.3301594
![]() |
[121] |
Feng Q, Zheng S, Zheng J (2018) The emerging role of micro RNAs in bone remodeling and its therapeutic implications for osteoporosis. Biosci Rep 38: BSR20180453. doi: 10.1042/BSR20180453
![]() |
[122] | Hemigou P, Poignard A, Beaujean F, et al. (2005) Percutaneous autologous bone marrow grafting for non-unions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 87: 1430-1437. |
[123] |
Kawaguchi H, Oka H, Jingushi S, et al. (2010) A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: A randomized placebo-controlled trial. J Bone Miner Res 12: 2735-2743. doi: 10.1002/jbmr.146
![]() |
[124] |
DiGiovanni CW, Lin SS, Baumhauer JF, et al. (2013) Recombinant human platelet derived growth factor-BB and beta-tricalcium phosphate (rhPDGF-BB/beta-TCP): An alternative to autologous bone graft. J Bone Joint Surg Am 95: 1184-1192. doi: 10.2106/JBJS.K.01422
![]() |
[125] |
Brighton CT, Black J, Friedenberg ZB, et al. (1981) A multicenter study of the treatment of non-unions with constant direct current. J Bone Joint Surg Am 63: 847-851. doi: 10.2106/00004623-198163050-00030
![]() |
[126] |
Brighton CT (1981) Treatment of non-unions of the Tibia with constant direct current (1980 Fitts Lecture, AAST). J Trauma 21: 189-195. doi: 10.1097/00005373-198103000-00001
![]() |
[127] |
Scott G, King JB (1994) A prospective, double blind trial of electrical capacitive coupling in the treatment of non-union of long bones. J Bone Joint Surg Am 76: 820-826. doi: 10.2106/00004623-199406000-00005
![]() |
[128] |
Sharrard WJ (1990) A double blind trial of pulsed electromagnetic fields for delayed union of tibial fractures. J Bone Joint Surg Br 72: 347-355. doi: 10.1302/0301-620X.72B3.2187877
![]() |
[129] |
Mollen B, De Silva V, Busse JW, et al. (2008) Electrical stimulation for long bone fracture healing: A meta-analysis of randomosed control trials. J Bone Joint Surg Am 90: 2322-2330. doi: 10.2106/JBJS.H.00111
![]() |
[130] |
Li S, Jiang H, Wang B, et al. (2018) Magnetic resonance spectroscopy for evaluating effect of pulsed electromagnetic fields on marrow adiposityin postmenopausal women with osteopenia. J Comput Assist Tomography 42: 792-797. doi: 10.1097/RCT.0000000000000757
![]() |
[131] |
Catalano A, Loddo S, Bellone F, et al. (2018) Pulsed electromagnetic fields modulate bpne metabolism via RANKL/OPG and Wnt/beta-catenin pathways in women with postmenopausal osteoporosis: A pilot study. Bone 116: 42-46. doi: 10.1016/j.bone.2018.07.010
![]() |
[132] |
Ziegler P, Nussler AK, Wilbrand B, et al. (2019) Pulsed electromagnetic field therapy improves osseous consolidation after high tibial osteotomy in elderly patients–A randomized placebo-controlled, double blind trial. J Clin Med 8: 2008. doi: 10.3390/jcm8112008
![]() |
[133] |
Leung KS, Lee WS, Tsui HF, et al. (2004) Complex tibial fracture outcomes following treatment with low-intensity pulsed ultrasound. Ultrasound Med Biol 30: 389-395. doi: 10.1016/j.ultrasmedbio.2003.11.008
![]() |
[134] |
Siska PA, Gruen GS, Pape HC (2008) External adjuncts to enhance fracture healing: What is the role of ultrasound? Injury 39: 1095-105. doi: 10.1016/j.injury.2008.01.015
![]() |
[135] |
Schortinghuis J, Bronckers AL, Stegenga B, et al. (2005) Ultrasound to stimulate early bone formation in a distraction gap: A double blind randomised clinical pilot trial in the edentulous mandible. Arch Oral Biol 50: 411-420. doi: 10.1016/j.archoralbio.2004.09.005
![]() |
[136] |
El-Bialy TH, Elgazzar RF, Megahed EE, et al. (2008) Effects of ultrasound modes on mandibular osteodistraction. J Dent Res 87: 953-957. doi: 10.1177/154405910808701018
![]() |
[137] |
Leung KS, Cheung WH, Zhang C, et al. (2004) Low intensity pulsed ultrasound stimulates osteogenic activity of human periosteal cells. Clin Orthop Relat Res 253-259. doi: 10.1097/00003086-200401000-00044
![]() |
[138] |
Pilla AA, Mont MA, Nasser PR, et al. (1990) Non-invasive low-intensity pulsed ultrasound accelerates bone healing in the rabbit. J Orthop Trauma 4: 246-253. doi: 10.1097/00005131-199004030-00002
![]() |
[139] | Busse JW, Bhandari M, Kulkarni AV, et al. (2002) The effect of low-intensity pulsed ultrasound therapy on time to fracture healing: A meta-analysis. CMAJ 166: 437-441. |
[140] | Heckman JD, Sarasohn-Kahn J (1997) The economics of treating tibia fractures. The cost of delayed unions. Bull Hosp Joint Dis 56: 63-72. |
[141] | Romano CL, Zavaterelli A, Meani E (2006) Biophysical treatment of septic non-unions. Archivio di Ortopedia e Reumatologia 117: 12-13. |
[142] |
Mundi R, Petis S, Kaloty R, et al. (2009) Low-intensity pulsed ultrasound: Fracture healing. Indian J Orthop 43: 132-140. doi: 10.4103/0019-5413.50847
![]() |
[143] | Schandelmaier S, Kaushal A, Lytvyn L, et al. (2017) Low intensity pulsed ultrasound for bone healing: A systematic review of randomised controlled trials. BMJ 356: j656. |
[144] | Yadollahpour A, Rashidi S (2017) Therapeutic applications of low-intensity pulsed ultrasound in osteoporosis. Asian J Pharm 11: S1-S6. |
[145] |
Farmer ME, Harris T, Madans JH, et al. (1989) Anthropometric indicators and hip fracture. The NHANES I epidemiologic follow-up study. J Am Geriatr Soc 37: 9-16. doi: 10.1111/j.1532-5415.1989.tb01562.x
![]() |
[146] |
Cosman F, Lindsay R, LeBoff MS, et al. (2014) Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 25: 2359-2381. doi: 10.1007/s00198-014-2794-2
![]() |
[147] | National Osteoporosis Foundation Osteoporosis exercise for strong bones. Available from: https://www.nof.org/patients/fracturesfall-prevention/exercisesafe-movement/osteoporosis-exercise-for-strong-bones/. |
[148] | Pfeifer M, Minne H (2005) Bone loading exercise recommendations for prevention and treament of osteoporosis. Int Osteoporosis Foundation . |
[149] | (2020) NIH Osteoporosis and Related Bone Disease National Resource Center. Health Topics: Osteoporosis. Available from: www.bones.nih.gov. |
[150] |
Carneiro MB, Alves DPL, Mercadante MT (2013) Physical therapy in the postoperative of proximal femur fracture in elderly. Literature review. Acta Ortop Bras 21: 175-178. doi: 10.1590/S1413-78522013000300010
![]() |
[151] |
Meys G, Kalmet PHS, Sanduleau S, et al. (2019) A protocol for permissive weight-bearing during allied health therapy in surgically treated fractures of the pelvis and lower extremities. J Rehabil Med 51: 290-297. doi: 10.2340/16501977-2532
![]() |
[152] |
Baer M, Neuhaus V, Pape HC, et al. (2019) Influence of mobilization and weight bearing on in-hospital outcome in geriatric patients with hip fractures. SICOT J 5: 4. doi: 10.1051/sicotj/2019005
![]() |
[153] |
Senderovich H, Kosmopoulos A (2018) An insight into the effect of exercises on the prevention of osteoporosis and associated fractures in high-risk individuals. Rambam Maimonides Med J 9: e0005. doi: 10.5041/RMMJ.10325
![]() |
[154] | Benedetti MG, Furlini G, Zati A, et al. (2018) The effectiveness of physical exercise on bone density in osteoporotic patients. BioMed Res Int . |
[155] | Erhan B, Ataker Y (2020) Rehabilitation of patients with osteoporotic fractures. J Clin Densitom In Press. |
[156] |
Atkins GJ, Welldon KJ, Wijenayaka AR, et al. (2009) Vitamin K promotes mineralization, osteoclast to osteocyte transition, and an anticatabolic phenotype by gamma-carboxylation-dependent and -independent mechanisms. Am J Physio Cell Physiol 297: C1358-1367. doi: 10.1152/ajpcell.00216.2009
![]() |
[157] |
Lee NK, Sowa H, Hinoi E, et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456-469. doi: 10.1016/j.cell.2007.05.047
![]() |
[158] | Yamaguchi M, Weitzmann MN (2011) Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing nF-kappa B activation. Int J Mol Med 27: 3-14. |
[159] |
Palermo A, Tuccinardi D, D'Onofrio L, et al. (2017) Vitamin K and osteoporosis: Myth or reality? Metabolism 70: 57-71. doi: 10.1016/j.metabol.2017.01.032
![]() |
[160] |
Rossini M, Bianchi G, Di Munno O, et al. (2006) Treatment of osteoporosis in clinical practice (TOP) study group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteopros Int 17: 914-921. doi: 10.1007/s00198-006-0073-6
![]() |
[161] |
Bischoff-Ferrari B, Giovannucci E, Willett WC, et al. (2006) Estimation of optimal serum concentration of 25-hydroxy vitamin D for multiple health outcomes. Am J Clin Nutr 84: 18-28. doi: 10.1093/ajcn/84.1.18
![]() |
[162] |
Holick MF, Siris ES, Binkley N, et al. (2005) Prevalence of vitamin D inadequacy among post menopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90: 3215-3224. doi: 10.1210/jc.2004-2364
![]() |
[163] |
Adani S, Giannini S, Bianchi G, et al. (2009) Vitamin D status and response to treatment in postmenopausal osteoporosis. Osteoporos Int 20: 239-244. doi: 10.1007/s00198-008-0650-y
![]() |
[164] | Merskey HE (1986) Classification of chronic pain: Description of chronic pain syndromes and definition of pain terms. Pain . |
[165] |
Catalano A, Martino G, Morabito N, et al. (2017) Pain in osteoporosis: From pathophysiology to therapeutic approach. Drugs Aging 34: 755-765. doi: 10.1007/s40266-017-0492-4
![]() |
[166] |
Edwards MH, Dennison EM, Sayer AA, et al. (2015) Osteoporosis and sarcopenia in older age. Bone 80: 126-130. doi: 10.1016/j.bone.2015.04.016
![]() |
[167] |
Lange U, Teichmann J, Uhlemann C (2005) Current knowledge about physiotherapeutic strategies in osteoporosis prevention and treatment. Rheumatol Int 26: 99-106. doi: 10.1007/s00296-004-0528-z
![]() |
[168] |
Ehde DM, Dillworth TM, Turner JA (2014) Cognitive-behavioural therapy for individuals with chronic pain: efficacy, innovations, and direction for research. Am Psycho 69: 153-166. doi: 10.1037/a0035747
![]() |
[169] |
Iwamoto J, Takeda T, Sato Y, et al. (2005) Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in postmenopausal women treated with alendronate. Aging Clin Exp Res 17: 157-163. doi: 10.1007/BF03324589
![]() |
[170] |
O'Connor JP, Lysz T (2008) Celecoxib, NSAIDs and the skeleton. Drugs Today (Barc) 44: 693-709. doi: 10.1358/dot.2008.44.9.1251573
![]() |
[171] | Vellucci R, Consalvo M, Celidoni L, et al. (2016) Implications of analgesics use in osteoporotic-related pain treatment: focus on opioids. Clin Cases Miner Bone Metab 13: 89-92. |
[172] |
Adolphson P, Abbaszadegan H, Jonsson U, et al. (1993) No effects of piroxicam on osteopenia and recovery after Colles' fracture. A randomized, double-blind, placebo-controlled, prospective trial. Arch Orthop Trauma Surg 112: 127-130. doi: 10.1007/BF00449987
![]() |
[173] | Davis TR, Ackroyd CE (1998) Non-steroidal anti-inflammatory agents in management of Colles' fractures. Br J Clin Prct 42: 184-189. |
[174] |
Bauer DC, Orwell ES, Fox KM, et al. (1996) Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk. Study of osteoporotic fractures research group. J Bone Miner Res 11: 29-35. doi: 10.1002/jbmr.5650110106
![]() |
[175] | Alkhiary YM, Gerstenfeld LC, Elizabeth K, et al. (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1–34). J Bone Joint Surg Am 87: 731-741. |
[176] |
Morgan EF, ZD Mason, Bishop G, et al. (2008) Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1–34) in metaphyseal bone healing. Bone 43: 1031-1038. doi: 10.1016/j.bone.2008.07.251
![]() |
[177] |
Jorgensen NR, Schwarz P (2011) Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep 9: 149-145. doi: 10.1007/s11914-011-0065-0
![]() |
[178] |
Sarahrudi K, Thomas A, Albrecht C, et al. (2012) Strongly enhanced levels of sclerostin during human fracture healing. J Orthop Res 30: 1549-1155. doi: 10.1002/jor.22129
![]() |
[179] |
Kamiya N (2012) The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol 5: 153-163. doi: 10.2174/1874467211205020153
![]() |